Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 9/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25138317 | 1.00 | STING1 (0.49) | STING1ALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL30191932 | 0.93 | STING1 (0.46) | STING1ALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL25037517 | 0.93 | STING1 (0.46) | STING1ALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL30882832 | 0.93 | STING1 (0.49) | STING1ALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL25037393 | 0.93 | STING1 (0.49) | STING1ALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL29256231 | 0.92 | STING1 (0.47) | STING1ALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL30191380 | 0.92 | MAPT (0.45) | STING1ALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL29256217 | 0.92 | MAPT (0.45) | STING1ALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL25037514 | 0.91 | STING1 (0.51) | STING1ALDH1A1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL25035493 | 0.91 | MAPT (0.49) | STING1ALDH1A1CYP2C9CYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115151304-B | Small molecule interferon gene stimulating factor (STING) antagonists | 库拉德夫制药私人有限公司 | 2025-02-11 | — | — | CN | claimed |
| CN-115151304-A | Small molecule interferon gene stimulating factor (STING) antagonists | 库拉德夫制药私人有限公司 | 2022-10-04 | — | — | CN | claimed |
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | STING1, CGAS, MAVS | STING1 1/4885ALDH1A1 3672/4885CYP2C9 3960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.